Galera Therapeutics Files 8-K Report
Ticker: GRTX · Form: 8-K · Filed: Apr 3, 2026 · CIK: 0001563577
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Galera Therapeutics filed an 8-K, but no juicy details yet.
AI Summary
On April 3, 2026, Galera Therapeutics, Inc. filed an 8-K report detailing other events. The filing does not contain specific financial figures or significant business updates beyond the reporting of the event itself.
Why It Matters
This filing indicates a corporate event has occurred for Galera Therapeutics, Inc., requiring disclosure to the public.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report of other events and does not contain information that inherently increases risk.
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Filer of the 8-K report
- 0001563577 (company) — CIK number for Galera Therapeutics, Inc.
- 2026-04-03 (date) — Filing date and period of report
FAQ
What type of event is reported in this 8-K filing?
This 8-K filing reports under Item 8.01, which pertains to 'Other Events'.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 3, 2026.
What is the CIK number for Galera Therapeutics, Inc.?
The CIK number for Galera Therapeutics, Inc. is 0001563577.
What is the business address of Galera Therapeutics, Inc.?
The business address is 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355.
What is the SIC code for Galera Therapeutics, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 747 words · 3 min read · ~2 pages · Grade level 12.8 · Accepted 2026-04-03 06:03:35
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share GRTX OTCQB Mark
Filing Documents
- d117348d8k.htm (8-K) — 24KB
- 0001193125-26-141187.txt ( ) — 134KB
- grtx-20260403.xsd (EX-101.SCH) — 2KB
- grtx-20260403_lab.xml (EX-101.LAB) — 18KB
- grtx-20260403_pre.xml (EX-101.PRE) — 11KB
- d117348d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GALERA THERAPEUTICS, INC. Date: April 3, 2026 By: /s/ J. Mel Sorensen, M.D. J. Mel Sorensen, M.D. President and Chief Executive Officer